Distribution Partner Secures Contract Relating to Cervical Cancer Screening
MISSISSAUGA, CANADA, October 27, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its quality assessment products (“QAPs™”) are supporting a testing program for Human Papilloma Virus (“HPV”) using molecular diagnostic (“MDx”) technology at Dublin’s The Coombe Hospital, in the Republic of Ireland, an EU member-state.
Microbix’s local distribution partner, The Medical Supply Company of Ireland (“MSC”), has secured a tender-based contract to supply goods and services to support this national-level MDx and HPV-based cervical cancer screening program. The program is being driven by the instrumentation and reagents of the Roche Diagnostics Corporation cobas® 6800/8800 Systems and cobas® HPV test system, with Microbix REDx® liquid-format IVD-regulated multiplex QAPs providing quality management system support to help ensure test accuracy. It is expected that the program will see regular participation by a majority of women of reproductive age within Ireland’s overall population of 5.1 million.
HPV is a family of over 100 virus sub-types, 14 of which are deemed “high-risk” as they may directly cause cancers, most notably cervical cancer, if not resolved by the immune system. Most sexually-active adults become infected with one or more HPV types and such infections can be persistent. MDx tests permit early detection and timely preventative healthcare by identifying those at-risk years before cancer develops.
However, MDx-based screening programs require rigorous quality systems and ongoing revalidation to ensure their accuracy. This includes creating workflow algorithms, implementing strict QC/QA practices, training staff to be proficient, and sourcing materials and methods to evaluate testing workflows. Microbix’s portfolio of HPV-directed QAPs are used to help ensure the ongoing accuracy of MDx testing.
Dr. Lisa Tang, Head of Sales and Marketing of MSC commented, “We are pleased to support this important women’s health initiative with Microbix’s HPV QAPs. We now look forward to the roll-out of MDx-based cervical cancer screening throughout the Republic of Ireland.”
An initial purchase order for HPV-directed QAPs has been received by Microbix and it is expected that recurring QAPs sales into Ireland will become routine. Microbix and its distribution partners are likewise targeting support of MDx and HPV-based cervical cancer screening programs in other countries, including within the EU and in North America.
Phil Casselli, Senior Vice President of Sales and Business Development of Microbix also commented, “Ireland provides an example of Microbix’s technological leadership by way of our HPV quality controls being selected to support another national HPV screening program. We are proud to have collaborated with Coombes, MSC, and Roche to help bring this program online.”
About Microbix Biosystems
Microbix Biosystems Inc. creates proprietary biological products for human health, with over 100 skilled employees and annualized sales targeting C$ 2.0 million per month. It makes a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of 10 international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products.
Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably viral transport medium (DxTM™) to stabilize patient samples for lab-based molecular diagnostic testing and Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots. Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada.
This news release includes “forward-looking information,” as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of Coombes, MSC, Roche, or any MDx screening programs, MDx testing for HPV or its relevance, the products or services of Microbix, Microbix’s business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its corporate presentation, regulatory compliance and approvals, sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity and timeliness of delivery), foreign currency and exchange rates, maintaining adequate working capital or raising further capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking information is inherently uncertain and that actual performance may be affected by many material factors, some of which are beyond the Company’s control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company’s judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information.
Please visit https://microbix.com or www.sedar.com for recent Microbix news and filings.
For further information, please contact Microbix at:
|Cameron Groome, CEO
Adelaide Capital Markets
(647) 203-8793 email@example.com
Copyright © 2023 Microbix Biosystems Inc.
Microbix®, DxTM™, Kinlytic®, QAPs™, and REDx™ are trademarks of Microbix Biosystems Inc.
Other companies’ names and products are protected by their respective trademarks.